Business Wire

Innovative New Products and Technology Advancing Worldwide Liver Disease Management Highlight Echosens 20th Anniversary

Share

Echosens, a high-technology company offering the FibroScan® portfolio of solutions, is pleased to celebrate its 20th consecutive year pioneering the field of liver diagnosis and management. Recognized worldwide as the reference for liver fibrosis and liver steatosis assessment, with more than 3,000+ peer-reviewed publications and 140+ international guidelines, Echosens continues to show an unparalleled commitment to innovation. In the past year alone Echosens launched three new global products all carefully designed to optimize the overall FibroScan experience.

A year ago, Echosens launched their flagship and most advanced product, the FibroScan Expert 630. This device is the complete non-invasive solution for liver disease management, powered by liver stiffness measurement (LSM by VCTE) CAP and spleen stiffness measurement (SSM by VCTE) as part of an overall assessment of the liver.

Echosens then launched SmartExam software, which unlocks three key benefits for users: improved reliability in the diagnosis and monitoring of steatosis with continuous CAP; extended usage among severely obese patients with deeper assessment of liver fibrosis and steatosis; and task automation features that enable physicians to dedicate more time to patient care.

Recently, Echosens launched FibroScan-based Agile scores to easily detect advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease (NAFLD) patients. Included on the free myFibroScan app, users can now assess a patient's liver health in just a few clicks, making interpreting results quicker and easier than ever.

“Our long-term commitment to innovation optimizes the FibroScan portfolio of solutions, representing a major step toward winning the worldwide battle against liver disease,” says Dominique Legros, Group CEO, Echosens. “We’re highly grateful to our team leaders and champions for continuing to challenge the status quo in improving the management of silent, underdiagnosed chronic liver disease, which includes NAFLD and its more severe form nonalcoholic steatohepatitis (NASH). A number of chronic liver diseases can be reversible if diagnosed early.”

He points to the FibroScan Expert 630 as an innovative tool designed to expand clinical capabilities in liver health assessment with the addition of SSM by VCTE. This tool potentially supplies a cost-effective, non-invasive modality for spleen and liver stiffness measurements that may be used as an aid in the diagnosis, monitoring and clinical management of adult patients with liver disease.

For more than two decades, Echosens has generated robust clinical data that is extremely valuable in helping providers, benefits decision-makers and payers understand how a point-of-care examination can improve the quality of specialist referrals – reducing waste from unnecessary and often invasive testing. This was validated in an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) and published in the September 2021 issue of the American Journal of Managed Care.

“Furthermore, the National Institute for Health and Care Excellence (NICE), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary care setting,” says Legros. “Additionally, new guidelines from the European Association for the Study of the Liver (EASL), a professional association for those researching liver disease, outlined an unprecedented level of recommendation for Echosens’ solutions.”

Jon Gingrich, CEO, Echosens North America, states, “During our anniversary year, it is gratifying to highlight the exciting technological advances we have developed and introduced to the healthcare industry. We have demonstrated our commitment to innovation and value in the field, reflected by the essential and actionable data to support and advance liver health management.”

Listen to episodes of eHealth Radio Network, featuring some of today’s leading innovators in healthcare and wellness.

About Echosens

Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 3,000 peer reviewed publications and 140 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Brittany Tedesco
CPR Communications
btedesco@cpronline.com
201.641.1911 x 14

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Temenos Announces Composable Banking Services on the Temenos Banking Cloud Platform18.1.2022 10:53:00 EET | Press release

Temenos (SIX: TEMN), the banking software company, today announced Composable Banking Services and Capabilities aligned to the BIAN (Banking Industry Architecture Network) service landscape on the Temenos Banking Cloud. In addition, Temenos delivers new banking services and technology advancements that create the market's most comprehensive, cloud-native platform for composable banking. These new banking services are showcased at Temenos Sales Kick-Off, 18-21 January and will be presented at Temenos Community Forum, 17-19 May 2022. Temenos has advanced its technology architecture and banking capabilities to deliver the most open and secure cloud-native platform for composing, extending or deploying banking capabilities at scale. New pre-composed banking services on the Temenos Banking Cloud can be rapidly consumed from a self-service portal, easily configured, extended or deployed anywhere. Composed Temenos Banking Services consist of pre-configured and pre-assembled Temenos Banking Ca

SES Appoints John-Paul Hemingway as Chief Strategy and Product Officer18.1.2022 10:50:00 EET | Press release

SES is adding a new Chief Strategy and Product Officer (CSPO) to its Senior Leadership Team, underscoring SES’s commitment to ideate, build and deliver the services and solutions that create the most value for SES customers and partners, as well as their end-users. John-Paul (JP) Hemingway is charged with translating SES's corporate vision into strategic action for the company's networks and video markets – including its target applications, strategic partnerships, portfolio of solutions, and the space and network assets required to deliver them. The newly-created function brings together the Corporate Strategy, Product, Commercial Operations, Fleet Development, Innovation and Marketing & Communications teams, and is part of SES’s drive to be the most customer-centric, product-led organisation in the industry. With Hemingway’s appointment as CSPO, SES is eliminating the role of SES Networks CEO while retaining the strong focus on its video and networks businesses and leveraging its inn

CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.18.1.2022 09:05:00 EET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd. (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, as indicated in the pre-announcement of the public tender offer published by CSL Limited on 14 December 2021. The transaction, has been unanimously approved by both companies’ Boards of Directors. The offer price for each registered share of Vifor Pharma Ltd. is USD 179.25 in cash. The public tender offer is subject to the offer conditions set forth in the offer prospectus, which includes the report of

Fujirebio Europe Launches the RoboBlot™ Instrument, a Fully Automated Solution for INNO-LIA® Score Assays18.1.2022 09:00:00 EET | Press release

Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the automated processing of the widely used INNO-LIA Score assays. The instrument is manufactured by Bee Robotics Ltd. and distributed by Fujirebio Europe. The system’s pre-programmed test protocols provide start-to-finish automation of strip-based INNO-LIA Score assays, from sample addition, over strip processing, image capture, to result interpretation and where applicable laboratory information system (LIS) communication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005350/en/ RoboBlot™ - an instrument for fully automated processing of INNO-LIA® tests from sample pipetting to strip reading and LiRAS® interpretation (Photo: Fujirebio) “High throughput testing and more automation are an increasingly pressing need for laboratories. The typical drawbacks of manual testing, such as long hands-on time, inconsistent ass

Fast Growing RegTech SteelEye Reports 88% Growth In 202118.1.2022 08:01:00 EET | Press release

SteelEye, the compliance technology and data analytics firm, has announced a record year of growth. Revenues increased 88 percent year-on-year in 2021 and the company now has over 120 institutional clients worldwide, with new clients including Oppenheimer Europe Ltd and JonesTrading. SteelEye – which is headquartered in the UK and has offices in London, New York, Paris, Bengaluru, and Braga – has seen increasing demand for its services as financial firms’ regulatory compliance needs have grown across the globe. In response, the business expanded to the United States last year, backed by $17 million funding rounds in 2020, and appointed RegTech veteran Brian Lynch to lead its US operations. Pressure from regulators and the increasing need to improve operational efficiency across the industry have encouraged more firms to replace legacy technologies through platforms like SteelEye. This demand is growing exponentially as remote and hybrid work patterns become the norm – requiring firms t

Faster Air Quality Mapping Thanks to Ricardo’s RapidAir Software18.1.2022 03:01:00 EET | Press release

RapidAir®, developed by the global air quality, energy and environment specialists, is the next generation dispersion modelling and policy support platform that enables users to test the impact of scenarios in minutes, supporting the identification of measures that will reduce traffic emissions and consequently improve public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005253/en/ RapidAir air quality software (Photo: Business Wire) The ground-breaking air quality dispersion modelling software has already been successfully used across Asia, Europe and the UK, supporting Clean Air Zone evaluations, traffic management measures and wider air quality management activities. In response to requests from clients, including transport and health professionals, Ricardo has developed a cloud-based RapidAir software, complimenting its consultancy offering and making the capabilities of RapidAir more accessible to profess

Megaport Announces Partnership with TD SYNNEX as Leading Network as a Service (NaaS) Vendor Partner18.1.2022 00:00:00 EET | Press release

Megaport Limited (ASX: MP1) ("Megaport"), a global leading Network as a Service (NaaS) provider, today announces a partnership with TD SYNNEX, a global IT distributor and solutions aggregator, to make Megaport’s global, private Software Defined Network (SDN) platform available to TD SYNNEX customers. “Bringing Megaport’s leading Network as a Service platform into the TD SYNNEX portfolio makes it easier for customers to modernize their network connectivity and connect quickly to leading cloud service providers,” said Rodney Foreman, Chief Revenue Officer at Megaport. “TD SYNNEX’s global scale and reach, combined with their expertise in IT solutions, makes them an ideal partner to expand our channel relationships.” "TD SYNNEX is committed to delivering IT solutions to our customers that unlock their growth," said Cheryl Neal, vice president of New Vendor Acquisition, TD SYNNEX. "Adding Megaport’s Network as a Service offerings to our vast portfolio of IT solutions enables our customers t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom